Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2011; 57(4): 12-20

Effects of cytokine-like polypeptide EMAP II and flutamide on the testosterone-stimulated prostate of castrated rats

Reznikov OH, Chaĭkovs'ka LV, Poliakova LI, Sachyns'ka OV

    V.Komissarenko Institute of Endocrinology and Metabolism, Kyiv, Ukraine


The effects of separate and combined administration of cytokine-like polypeptide EMAP II and flutamide, a non-steroid antiandrogen, on morphology and function of the ac­cessory sexual glands in castrated rats stimulated with test­osterone propionate were studied. We found antiangiogenic, procoagulating and proapoptotic effects of EMAP II in the ventral prostate. Combined administration of the preparations enhanced their antiprostatic effects, which were manifested in inhibition of the androgen-dependent processes in prostate tissues, changes in proliferation and apoptosis, DNA, RNA and protein contents. We conclude that combined administra­tion of EMAP II and flutamide can be used for development of new therapeutic modalities in prostate cancer.

Keywords: EMAP II, flutamide, apoptosis, proliferation, ratprostate, castration, testosterone propionate.


  1. Dubrovsky AL, Brown J., Kornelyuk A.I. Bacterial expression of full-length and truncated forms of the EMAP II cytokine and the mammalian cytokine-like domain of mammalian tyrosyl-tRNA synthetase . Biopolymers and Cell. 2000. 16, N 3. P. 229-235. CrossRef  
  2. Shatkin A. Colorimetric methods for determining DNA, RNA and protein . Methods of Virology and Molecular Biology . Ed. K. Hubel, M.P. Saltzman. M .: Mir, 1972. P. 84-89.
  4. Alam S., McNeel D.G. DNA vaccines for the treatment of prostate cancer . Expert Rev Vaccines. 2010. N 7. P. 731-745. CrossRef PubMed
  6. Antonarakis E.S., Carducci M.A., Eisenberger M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer . Cancer Lett. 2010. 291, N 1. P. 1-13. CrossRef PubMed PubMedCentral
  8. Aragon-Ching J.B. Dahut W.L. VEGF inhibitors and prostate cancer therapy . Curr Mol Pharmacol. 2009. 2,N 2. P.161-168. CrossRef PubMed PubMedCentral
  10. Awasthi N., Schwarz M.A., Verma V., Cappiello C, Schwarz R.E. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling . Lab Invest. 2009. 89, N 1. P. 38-46. CrossRef PubMed
  12. Chen Y., Clegg N.J., Scher H.I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target . Lancet Oncol. 2009.-10,N 10. P.981-991. CrossRef  
  13. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence . Endocri­nology. 1998. 139, N 2. P. 441-442. CrossRef PubMed
  15. Franck-Lissbrant I., Hflggstrirm S., Damber J.E., Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats . Ibid. 1998. 139, N 2. P. 451-456. CrossRef PubMed
  17. Ivakhno S. S., Kornelyuk A. I. Cytokine-like activities of some aminoacyl-tRNA synthetases and auxiliary p43 cofactor of aminoacylation reaction and their role in oncogenesis . Exper. Oncol. 2004. 26, N 4. P. 250-255.
  19. Kao J., Houck K., Fan Y., Haehnel I., Libutti S.K., Kayton M.L., Grikscheit T., Chabot J., Nowygrod R., Greenberg S. Characterization of a novel tumor-de­rived cytokine Endothelia-monocyte activating polypeptide II . J. Biol. Chem. 1994. 9, N 40. P.25106-25119.
  21. Kao J., Ryan J., Brett G., Chen J., Shen H., Fan Y.G., Godman G., Familletti P.C., Wang F., Pan Y.C. Endot­helial monocyte-activating polypeptide II. A novel tu­mour-derived polypeptide that activates host-response mechanisms . Ibid. 1992. 267, N 28. P. 20239- 20247.
  23. Li Y, Cozzi P.J. Angiogenesis as a strategic target for prostate cancer therapy . Med Res Rev. 2010. 30, N 1. P. 23-66.
  25. Shibata Y, Kashiwagi B., Arai S., Fukabori Y, Suzuki K., Honma S., Yamanaka H. Direct regulation of pros­tate blood flow by vascular endothelial growth factor and its participation in the androgenic regulation of prostate blood flow in vivo . Endocrinology. 2004. 145, N 10. P. 4507-4512. CrossRef PubMed
  27. Shibata Y, Ono Y, Kashiwagi B., Suzuki K., Fukabori Y, Honma S., Yamanaka H. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate . Urology. 2003. 62, N 5. P. 942-946. CrossRef  
  28. Reddy G.P., Barrack E.R., Dou Q.P., Menon M., Pelley R., Sarkar F.H., Sheng S. Regulatory processes affect­ing androgen receptor expression, stability, and func­tion: potential targets to treat hormone-refractory pros­tate cancer . J. Cell Biochem. 2006. 98, N 6. P. 1408-1423. CrossRef PubMed
  30. Vozianov A., Reznikov A., Klimenko I. Androgen dep­rivation strategy in prostate cancer Kyiv: Naukova Dumka, 2001. 240 p.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.